Wednesday, 3 July 2013

Silent Killer: Recent Advances in Cardiovascular Disease by

Here are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace.

To Read The Complete Report with  TOC :-

Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/reward ratio for any company willing to participate needs to be carefully considered.

This report provides you with a systematic appraisal into the current and future CV market, including...

A detailed review of the leading brands and how they are being positioned in the market, in addition to the potential impact of generics

  • Assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical development where proof of concept data has been established
  • Review of products that are ‘Waiting in the Wings’ in early-stage clinical development where Point-of-Care data is being gathered
  • Analysis of the potential of ‘Long Shots’ which represent new and innovative products where the scientific rationale has yet to be fully tested
  • Antilipidemics

The lowering of ‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) has been shown to reduce the chance of a heart attack and death in people who have an elevated risk of developing heart disease or who already have heart disease. Several drug classes are currently available to treat a range of lipid disorders; each has a different mechanism of action, safety profile and impact on blood lipid profiles to different degrees.

To Buy a Copy Of This Report:-

Key drugs covered by the report include

  • Leading brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and Partners), etc...
  • Recent generics - Atorvastatin, etc...
  • Ones to watch - Alirocumab (Sanofi/Regeneron Pharmaceuticals), AMG 145 (Amgen), Anacetrapid (Merck & Co), etc...
  • Waiting in the wings - RG 7652 (Roche), RN-316 (Pfizer), DRL-17822 (Dr Reddy), etc...
  • Long shots - ALN PCS (Alnylam/The Medicine Company), etc...
  • Just some of the key questions answered include
  • Why are statins the gold stand in lipid lowering therapies and which is the most effective at lowering LDL-C?
  • Will AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin reaches the market?
  • Why are PCSK9 inhibitors important to cardiologists and which drugs are leading the field?
  • Kynamro approved in the US but not in Europe… what next?
  • What new HDL-C modulating therapies are in development?
  • What new products are in development from BMS/Simcere; Dr Reddy and DezimaPharma?

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

No comments:

Post a Comment